79 related articles for article (PubMed ID: 8596890)
1. [Utility of molecular biology in the diagnosis of acute leukemia and evaluation of the residual disease].
Gabert J
Rev Prat; 1996 Jan; 46(1):42-7. PubMed ID: 8596890
[TBL] [Abstract][Full Text] [Related]
2. [Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease].
Földi J; Páldi HP; Nahajevszky S; Jakab K; Regéczi N; Pálóczi K
Orv Hetil; 2001 May; 142(21):1097-102. PubMed ID: 11449838
[TBL] [Abstract][Full Text] [Related]
3. Assessment of residual disease in acute leukemia by means of polymerase chain reaction.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Pérez-Romano B; Ruiz-Argüelles A; Ramírez-Cisneros FJ; López-Martínez B; López-Tapia JD; Rivadeneyra-Espinoza L
Rev Invest Clin; 2000; 52(2):118-24. PubMed ID: 10846434
[TBL] [Abstract][Full Text] [Related]
4. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
5. Detection of minimal residual disease in acute leukemia patients.
van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
7. Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients.
Olesen LH; Clausen N; Dimitrijevic A; Kerndrup G; Kjeldsen E; Hokland P
Br J Haematol; 2004 Oct; 127(1):59-66. PubMed ID: 15384978
[TBL] [Abstract][Full Text] [Related]
8. [Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases].
Jäger U; Laczika K; Scholten C; Mitterbauer M; Novak M; Lechner K
Wien Klin Wochenschr; 1996; 108(20):634-9. PubMed ID: 9005678
[TBL] [Abstract][Full Text] [Related]
9. [Detection of minimal residual leukemic cells in acute leukemia].
Irimajiri K
Rinsho Ketsueki; 1990 Apr; 31(4):409-15. PubMed ID: 2199697
[No Abstract] [Full Text] [Related]
10. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
11. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
12. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
13. [Minimal residual disease in childhood acute leukemias].
Pawińska K; Balwierz W; Baran J
Przegl Lek; 2006; 63(1):41-3. PubMed ID: 16892899
[TBL] [Abstract][Full Text] [Related]
14. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
[TBL] [Abstract][Full Text] [Related]
16. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
17. The use of PCR technology for detecting minimal residual disease in patients with leukemia.
Radich JP
Rev Immunogenet; 1999; 1(2):265-78. PubMed ID: 11253952
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge technologies in the evaluation of bone marrow samples.
Larson RS; McCurley TL
Clin Lab Sci; 1996; 9(6):354-7. PubMed ID: 10165117
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.
Babusíková O; Glasová M; Koníková E; Kusenda J
Neoplasma; 1996; 43(6):367-72. PubMed ID: 8996560
[TBL] [Abstract][Full Text] [Related]
20. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]